Sneha Saxena, PhDMassachusetts General Hospital2022 James A. Harting Scientific Scholar Award Targeting ovarian cancer by exploiting a novel type of replication stress induced by unprocessed uracil in DNA Despite decades of work to develop new treatments, the five-year survival of patients with advanced ovarian cancer is between 10-30 percent. Hence, there is a pressing need […]
Read More
Sarah Gitto, PhDUniversity of Pennsylania2022 Pape Family Scientific Scholar Award Transcriptomic and proteomic analysis of tumor-specific TILs to enhance immunotherapy in ovarian cancer Immunotherapies aim to enhance the immune system’s capability of eliminating disease within the body. Often, immunotherapy for cancer targets a type of immune cell called T cells to activate their ability to […]
Read More
Using genetic predictors of CA125 to improve personalized ovarian cancer screening Most ovarian cancer cases are currently diagnosed at late stage when less than half of the women will live five years after their diagnosis. In contrast, ovarian cancer cases diagnosed at an early stage have more than 90% living after five years from diagnosis. […]
Read More
Nerves as novel actors in the tumor microenvironment: the role of exosomes in ovarian cancer tumor innervation Although advances in surgery and chemotherapy for ovarian cancer have improved survival, most women with ovarian cancer will experience recurrence of their disease. Unfortunately, recurrent ovarian cancers respond poorly to chemotherapy and are incurable, highlighting the need for […]
Read More
Tao Wu, PhDBaylor College of Medicine2020 Scientific Scholar Award Targeting Epigenetic Landscape Reprogramming to Combat Drug-resistance in Ovarian Cancer Despite major improvements in therapeutic approaches to ovarian cancer, the ability of tumors to develop resistance to anti-cancer drugs remains the major challenge in achieving longer-lasting remission. One of the ways drug resistance is thought to […]
Read More
T. Rinda Soong, MD, PhDUniversity of Pittsburgh2020 Scientific Scholar Award Early Serous Tubal Proliferations as Alternate Precursors of High-Grade Serous Carcinoma Identifying the origins of high grade serous ovarian cancer can help us understand how to prevent this disease or detect it at earlier, more treatable stages. Precancerous changes in fallopian tube tissue known as […]
Read More
Rosemary Foster, PhDMassachusetts General Hospital Identification and Characterization of the Ovarian Cancer Stem Cell Cancer stem cells have recently been identified in some solid tumors and are thought to drive tumor formation. Most tumors likely contain rare subpopulations of stem-like cells that would serve as critical targets of more clinically effective therapies. Our research experiments […]
Read More
Melissa Fishel, PhDIndiana University School of Medicine Enhancement of ovarian cancer to chemotherapeutics agents, cisplatin and TMZ, using small molecules, BG and MX With the exception of a small percentage of patients presenting with stage IA/IB ovarian cancer, surgery along is inadequate treatment. However, virtually all patients who die from ovarian cancer have intrinsic or […]
Read More
Mary Zhang, PhDUniversity of South Florida Role of HDAC6 and its novel substrate cortactin in ovarian cancer cell motility HDACs are a group of enzymes that regulate cell growth and migration, and hence are likely involved with the metastases of ovarian cancer. This study will examine the role between these enzymes and the molecular events […]
Read More
Jason Wilken, PhD, BSYale University Overcoming Primary Herceptin Resistance in Ovarian Cancer Herceptin, a therapeutic antibody that targets ErbB2 and has a well-tolerated safety profile has proven exceptionally useful as a treatment for ErbB2+ breast cancer patients. Surprisingly, Herceptin has proven to be ineffective as a treatment option for ovarian cancer. Dr. Wilken, with the […]
Read More